Edwin Choy

Aug 27, 2024 | nature.com | Yu-Hang Xing |Rémi Buisson |Beverly Naigles |Mary Awad |Raffaele Renella |Edwin Choy | +2 more

AbstractEWS fusion oncoproteins underlie several human malignancies including Desmoplastic Small Round Cell Tumor (DSRCT), an aggressive cancer driven by EWS-WT1 fusion proteins. Here we combine chromatin occupancy and 3D profiles to identify EWS-WT1-dependent gene regulation networks and target genes. We show that EWS-WT1 is a powerful chromatin activator controlling an oncogenic gene expression program that characterizes primary tumors.

Aug 15, 2024 | targetedonc.com | Jordyn Sava |Edwin Choy

In this episode of Targeted Talks, Edwin Choy, MD, PhD, director of the sarcoma program at the Division of Hematology Oncology at Massachusetts General Hospital, a founding member of Mass General Brigham, and associate professor of medicine at Harvard Medical School, delves into the recent approval of afamitresgene autoleucel (afami-cel; Tecelra) for the treatment of patients with advanced synovial sarcoma. “Afami-cel is a T-cell receptor therapy.

Aug 2, 2024 | targetedonc.com | Edwin Choy

Edwin Choy, MD, PhD, director of the Sarcoma Program at the Division of Hematology Oncology at Massachusetts General Hospital, a founding member of Mass General Brigham, associate professor of medicine at Harvard Medical School, discusses the mechanism of action of afamitresgene autoleucel (afami-cel; Teclera) and the recent accelerated approval from the FDA for patients with advanced synovial sarcoma. Transcription:0:09 | Afami-cel is a T-cell receptor therapy.

Jul 26, 2023 | targetedonc.com | Edwin Choy

Edwin Choy, MD, director of the Sarcoma Program at the Division of Hematology Oncology at Massachusetts General Hospital, a founding member of Mass General Brigham, associate professor of medicine at Harvard Medical School, provides key recommendations for community oncologists treating patients with gastrointestinal stromal tumor (GIST).